0001415889-24-016934.txt : 20240614
0001415889-24-016934.hdr.sgml : 20240614
20240614163028
ACCESSION NUMBER: 0001415889-24-016934
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240613
FILED AS OF DATE: 20240614
DATE AS OF CHANGE: 20240614
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: ROTHBLATT MARTINE A
CENTRAL INDEX KEY: 0001106578
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-26301
FILM NUMBER: 241045332
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: UNITED THERAPEUTICS Corp
CENTRAL INDEX KEY: 0001082554
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 521984749
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1000 SPRING ST
CITY: SILVER SPRING
STATE: MD
ZIP: 20910
BUSINESS PHONE: 3016089292
MAIL ADDRESS:
STREET 1: 1000 SPRING ST
CITY: SILVER SPRING
STATE: MD
ZIP: 20910
FORMER COMPANY:
FORMER CONFORMED NAME: UNITED THERAPEUTICS CORP
DATE OF NAME CHANGE: 19990324
4
1
form4-06142024_040622.xml
X0508
4
2024-06-13
0001082554
UNITED THERAPEUTICS Corp
UTHR
0001106578
ROTHBLATT MARTINE A
C/O UNITED THERAPEUTICS CORPORATION
1000 SPRING STREET
SILVER SPRING
MD
20910
true
true
false
false
Chairperson & CEO
1
Common Stock
2024-06-13
4
M
0
3600
129.49
A
3730
D
Common Stock
2024-06-13
4
S
0
146
279.7501
D
3584
D
Common Stock
2024-06-13
4
S
0
125
280.725
D
3459
D
Common Stock
2024-06-13
4
S
0
230
281.6571
D
3229
D
Common Stock
2024-06-13
4
S
0
393
283.9455
D
2836
D
Common Stock
2024-06-13
4
S
0
430
284.7536
D
2406
D
Common Stock
2024-06-13
4
S
0
791
285.8421
D
1615
D
Common Stock
2024-06-13
4
S
0
367
286.8626
D
1248
D
Common Stock
2024-06-13
4
S
0
1118
287.6442
D
130
D
Common Stock
166
I
By Spouse
Common Stock
245909
I
By Trust
Common Stock
2706
I
By Trust
Common Stock
28170
I
By Trust
Common Stock
324518
I
By Trust
Common Stock
45596
I
By Trust
Stock Options
129.49
2024-06-13
4
M
0
3600
0
D
2014-12-31
2024-12-31
Common Stock
3600
176669
D
This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person on August 4, 2023. This plan will continue until the earlier of: (a) exhaustion of a tranche of 723,869 stock options that expire December 31, 2024; or (b) August 31, 2024.
This transaction was executed in multiple trades at prices ranging from $279.05 to $279.76. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
This transaction was executed in multiple trades at prices ranging from $280.29 to $281.04. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
This transaction was executed in multiple trades at prices ranging from $281.34 to $281.90. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
This transaction was executed in multiple trades at prices ranging from $283.30 to $284.27. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
This transaction was executed in multiple trades at prices ranging from $284.30 to $285.28. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
This transaction was executed in multiple trades at prices ranging from $285.30 to $286.25. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
This transaction was executed in multiple trades at prices ranging from $286.31 to $287.30. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
This transaction was executed in multiple trades at prices ranging from $287.32 to $288.22. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Shares held in family trusts as to which the Reporting Person is sole trustee and sole beneficiary or co-trustee and settlor with power to revoke.
Shares held in family trusts as to which the Reporting Person is sole trustee and members of the Reporting Person's immediate family are beneficiaries.
Shares held in family trusts as to which the Reporting Person's spouse is sole trustee and sole beneficiary or co-trustee and settlor with power to revoke.
Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries.
Shares held in family trusts as to which the Reporting Person's spouse shares investment power and the Reporting Person and/or immediate family members are beneficiaries.
/s/ John S. Hess, Jr. under Power of Attorney
2024-06-14